AELIS Aelis Farma SA

0.8774USD0.8000 EUR · EPA-1.48%Mkt Cap: 11.96M USDP/E: —

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacolo…

Key Statistics

Company
Market Cap11.96M USD
Enterprise Value9.57M USD
Revenue (TTM)2.40M USD
Gross Profit3.93M USD
Net Income (TTM)-7.06M USD
Revenue/Share0.18 USD
Last Price0.8774 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0014007ZB4
Valuation
P/E (Trailing)—
P/E (Forward)4.71
PEG—
EV/EBITDA-1.98
EV/Revenue3.98
P/S4.98
P/B4.73
EPS (TTM)-0.36 USD
EPS (Forward)0.19 USD
52W Range
0.669011% of range2.523
52W High2.523 USD
52W Low0.6690 USD
Profitability
Gross Margin163.46%
Oper. Margin-204.93%
EBITDA Margin-200.68%
Profit Margin-216.29%
ROE-144.94%
ROA-53.40%
ROIC-265.33%
ROCE-63.84%
Growth
Revenue Growth31.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.87M USD
CapEx (TTM)4.39K USD
FCF Margin-68.57%
FCF Yield-13.78%
Net Debt-2.46M USD
Net Debt/EBITDA0.51
Net Debt/FCF—
Balance Sheet
Debt/Equity1.49
Current Ratio9.80
Quick Ratio9.48
Book Value/Sh0.19 USD
Cash/Share0.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.63M
Float4.07M
Insiders36.44%
Institutions26.79%
Technical
SMA 500.9124 (-3.8%)
SMA 2001.197 (-26.7%)
Beta0.66
S&P 52W Chg12.00%
Avg Vol (30d)32.24K
Avg Vol (10d)64.03K
Technical Indicators
RSI (14)47.5
MACD0.0192
MACD Signal0.0145
MACD Hist.+0.0047
BB Upper1.128 USD
BB Middle0.8772 USD
BB Lower0.6260 USD
BB Width57.28%
ATR (14)0.0710 USD
Vol Ratio (20d)0.45x

About Aelis Farma (EPA: AELIS)

›

Aelis Farma (EPA: AELIS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.

The shares were at 0.8000 EUR on 19 November 2026, down 30.4% over 52 weeks. Its 52-week range is 0.6100 EUR to 2.300 EUR: the price is 65.2% below the high and 31.1% above the low.

Its market capitalisation is 10.91M EUR.

Aelis Farma reports return on equity of -144.9%, an operating margin of -204.9% and revenue up 31.6% year over year.

It holds more cash than debt, a net cash position of 2.24M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 30 March 2027.